# Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers

> **NCT07033585** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair** · enrollment: 600 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes
- **DRUG:** China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

## Key facts

- **NCT ID:** NCT07033585
- **Lead sponsor:** Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-15
- **Primary completion:** 2026-10-18
- **Final completion:** 2026-11-28
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07033585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07033585, "Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07033585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*